New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer

Nutrition and Cancer

Volumn 64, Issue 1, 2012, Pages 4-22

  Connors, Shahnjayla K ^a   Chornokur, Ganna ^a   Kumar, Nagi B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; EPIGALLOCATECHIN; GREEN TEA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME;

APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOPROPHYLAXIS; HUMAN; METASTASIS; NONHUMAN; ORBIT METASTASIS; PROSTATE CANCER; REVIEW; TUMOR GROWTH;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CATECHIN; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TEA;

EID: 84856852486     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.630158     Document Type: Review

References (195)

1. American Cancer Society: Cancer Facts and Figures 2010. American Cancer Society, Atlanta, GA, 2010.
2. Bostwick DG and Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 17, 360-379, 2004. (Pubitemid 41646613)
3. Epstein JI and Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 175, 820-834, 2006. (Pubitemid 43199991)
4. Kraft A,Weindel K, Ochs A, Marth C, Zmija J,.et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85, 178-187, 1999. (Pubitemid 29031373)
5. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P,.et al. Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int 99, 908-915, 2007. (Pubitemid 46439577)
6. Giovannuci E. Epidemiologic characteristics of prostate cancer. Cancer 75, 1766-1777, 1995.
7. Johnson JJ, Bailey HH, andMukhtar H. Green tea polyphenols for prostate cancer chemoprevention: A translational perspective. Phytomedicine 17, 3-13, 2010.
8. Wynder EL, Rose DP, and Cohen LA: Nutrition and prostate cancer: A proposal for dietary intervention. Nutr Cancer 22, 1-10, 1994. (Pubitemid 24233872)
9. Jian L, Xie LP, Lee AH, and Binns CW: Protective effect of green tea against prostate cancer: A case-control study in southeast China. Int J Cancer 108, 130-135, 2004. (Pubitemid 37444455)
10. Nelson WG: Agents in development for prostate cancer prevention. Expert Opin Investig Drugs 13, 1541-1554, 2004. (Pubitemid 39625140)
11. Division of Cancer Prevention and Control: Clinical development plan: Tea extracts, green tea polyphenols, epigallocatechin gallate. J Cell Biochem 26, 236-257, 1996.
12. Balentine DA, Wiseman SA, and Bouwens LC: The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37, 693-704, 1997. (Pubitemid 127349613)
13. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM,.et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 12, 383-390, 2003. (Pubitemid 37338812)
14. Bushman JL: Green tea and cancer in humans: A review of the literature. Nutr Cancer 31, 151-159, 1998. (Pubitemid 28481848)
15. Higdon JV and Frei B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43, 89-143, 2003. (Pubitemid 38552312)
16. Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E,.et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 25, 1-14, 1996. (Pubitemid 27078305)
17. Yang CS, Lambert JD, Ju J, Lu G, and Sang S. Tea and cancer prevention: Molecular mechanisms and human relevance. Toxicol Appl Pharmacol 224, 265-273, 2007. (Pubitemid 47592860)
18. Borrelli F, Capasso R, Russo A, and Ernst E. Systematic review: Green tea and gastrointestinal cancer risk. Aliment Pharmacol Ther 19, 497-510, 2004. (Pubitemid 38387176)
19. Lambert JD and Yang CS: Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res 523-524, 201-208, 2003. (Pubitemid 36293247)
20. Liang W, Binns CW, Jian L, and Lee AH: Does the consumption of green tea reduce the risk of lung cancer among smokers? Evid Based Complement Alternat Med 4, 17-22, 2007. (Pubitemid 46410888)
21. Sun CL, Yuan JM, Koh WP, and Yu MC: Green tea, black tea and breast cancer risk: A meta-analysis of epidemiological studies. Carcinogenesis 27, 1310-1315, 2006. (Pubitemid 43985405)
22. Woolcott CG, KingWD, andMarrett LD: Coffee and tea consumption and cancers of the bladder, colon and rectum. Eur J Cancer Prev 11, 137-145, 2002. (Pubitemid 34478430)
23. Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G,.et al. Tea consumption and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 18, 341-345, 2009.
24. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA,.et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 15, 2473-2476, 2006. (Pubitemid 46048307)
25. LeeMJ, Maliakal P, Chen L, Meng X, Bondoc FY,.et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin- 3-gallate by humans: Formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11, 1025-1032, 2002. (Pubitemid 35192653)
26. Weinshilboum RM, Otterness DM, and Szumlanski CL: Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39, 19-52, 1999. (Pubitemid 29222550)
27. Mukhtar H and Ahmad N. Tea polyphenols: Prevention of cancer and optimizing health. Am J Clin Nutr 71, 1698S-1702S; discussion, 1703S-1694S, 2000.
28. Sang S, Lambert JD, Ho CT, and Yang CS: The chemistry and biotransformation of tea constituents. Pharmacol Res 64, 87-99, 2011.
29. Yuan JM, Sun C, and Butler LM: Chapter 8. Tea and cancer prevention:epidemiological studies. Pharmacol Res 64, 123-135, 2011.
30. Thakur VS, Gupta K, and Gupta S. The chemopreventive and chemotherapeutic potentials of tea polyphenols. Curr Pharm Biotechnol, Epub ahead of print April 5, 2011.
31. Hamilton-Miller JM: Antimicrobial properties of tea (Camellia sinensis L.). Antimicrob Agents Chemother 39, 2375-2377, 1995.
32. Katiyar S and Mukhtar H. Tea in chemoprevention of cancer: Epidemiologic and experimental studies. Int J Oncol 8, 221-238, 1996.
33. Liao S, Kao YH., and Hiipakka RA: Green tea: biochemical and biological basis for health benefits. Vitam Horm 62, 1-94, 2001. (Pubitemid 33805701)
34. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM,.et al. Cancer prevention with natural compounds. Semin Oncol 37, 258-281, 2010.
35. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA,.et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57, 46-51, 2001.
36. Dou QP: Molecular mechanisms of green tea polyphenols. Nutr Cancer 61, 827-835, 2009.
37. Greenwald P and Kelloff GJ: The role of chemoprevention in cancer control. IARC Sci Publ, 13-22, 1996.
38. Khan N, Adhami VM, and Mukhtar H. Review: Green tea polyphenols in chemoprevention of prostate cancer: Preclinical and clinical studies. Nutr Cancer 61, 836-841, 2009.
39. Gupta S, Hastak K, Ahmad N, Lewin JS, and Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98, 10350-10355, 2001. (Pubitemid 32803023)
40. Greenwald P. Clinical trials in cancer prevention: Current results and perspectives for the future. J Nutr 134, 3507S-3512S, 2004. (Pubitemid 39587597)
41. Khan N, Afaq F, andMukhtar H. Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid Redox Signal 10, 475-510, 2008.
42. Khan N and Mukhtar H. Tea polyphenols for health promotion. Life Sci 81, 519-533, 2007. (Pubitemid 47212236)
43. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R,.et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10, 53-58, 2001. (Pubitemid 32106044)
44. ChowHH, CaiY,Hakim IA, Crowell JA, Shahi F,.et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9, 3312-3319, 2003. (Pubitemid 37082725)
45. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J,.et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11, 4627-4633, 2005. (Pubitemid 40825654)
46. UllmannU,Haller J, Decourt JD, Girault J, Spitzer V,.et al. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Int Vitam Nutr Res 74, 269-278, 2004. (Pubitemid 39421008)
47. Ullmann U, Haller J, Decourt JP, Girault N, Girault J,.et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J IntMed Res 31, 88-101, 2003. (Pubitemid 36553307)
48. AhmadN, Feyes DK, Nieminen AL,Agarwal R, andMukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89, 1881-1886, 1997. (Pubitemid 28009824)
49. Ahmad N, Gupta S, and Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 376, 338-346, 2000. (Pubitemid 30210882)
50. Albrecht DS, Clubbs EA, Ferruzzi M, and Bomser JA: Epigallocatechin-3- gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEKindependent ERK1/2 activation. Chem Biol Interact 171, 89-95, 2008. (Pubitemid 350191843)
51. Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M,.et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25, 2217-2224, 2004. (Pubitemid 39534860)
52. Smith DM, Wang Z, Kazi A, Li LH, Chan TH,.et al. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 8, 382-392, 2002. (Pubitemid 35346218)
53. Sartippour MR, Shao ZM, Heber D, Beatty P, Zhang L,.et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 132, 2307-2311, 2002. (Pubitemid 34851667)
54. Hsu A, Bruno RS, Lohr CV, Taylor AW, Dashwood RH,.et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFkappaB pathway in the Noble rat model. J Nutr Biochem 22, 502-510, 2010.
55. Nair S, Barve A, Khor TO, Shen GX, Lin W,.et al. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC- 3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 31, 1223-1240, 2010.
56. Zhou JR, Yu L, Zhong Y, and Blackburn GL: Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 133, 516-521, 2003. (Pubitemid 36172909)
57. Chen X, Yu H, Shen S, and Yin J. Role of Zn2+in epigallocatechin gallate affecting the growth of PC-3 cells. J Trace Elem Med Biol 21, 125-131, 2007. (Pubitemid 46702597)
58. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, and Rath M. In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: Evaluation of tumor growth and immunohistochemistry. In Vivo 19, 179-183, 2005.
59. Yu HN, Yin JJ, and Shen SR: Growth inhibition of prostate cancer cells by epigallocatechin gallate in the presence of Cu2+. J Agric Food Chem 52, 462-466, 2004.
60. Morrissey C, Brown M, O'Sullivan J, Weathered N, Watson RW,.et al. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells. Int J Urol 14, 545-551, 2007. (Pubitemid 46985545)
61. Adhami VM, Malik A, ZamanN, Sarfaraz S, Siddiqui IA,.et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro nd in vivo. Clin Cancer Res 13, 1611-1619, 2007. (Pubitemid 46450454)
62. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 125, 589-597, 1999. (Pubitemid 29502339)
63. Chen L, LeeMJ, Li H, and Yang CS: Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 25, 1045-1050, 1997. (Pubitemid 27396491)
64. Moyers SB and Kumar NB: Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials. Nutr Rev 62, 204-211, 2004. (Pubitemid 38702863)
65. Paschka AG, Butler R, and Young CY: Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3- gallate. Cancer Lett 130, 1-7, 1998. (Pubitemid 28425331)
66. Suganuma M, Okabe S, Sueoka N, Sueoka E, Matsuyama S,.et al. Green tea and cancer chemoprevention. Mutat Res 428, 339-344, 1999. (Pubitemid 29389704)
67. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR,.et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19, 1830-1838, 2001. (Pubitemid 32230886)
68. Choan E, Segal R, Jonker D, Malone S, Reaume N,.et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 23, 108-113, 2005. (Pubitemid 40616301)
69. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR,.et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97, 1442-1446, 2003. (Pubitemid 36297774)
70. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G,.et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 66, 1234-1240, 2006. (Pubitemid 43165995)
71. Brausi M, Rizzi F, and Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: Two years later. A follow-up update. Eur Urol 54, 472-473, 2008.
72. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M,.et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2, 673-682, 2009.
73. Lee MJ, Wang ZY, Li H, Chen L, Sun Y,.et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev 4, 393-399, 1995.
74. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC,.et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7, 351-354, 1998. (Pubitemid 28354149)
75. Yang CS, Lee MJ, and Chen L: Human salivary tea catechin levels and catechin esterase activities: Implication in human cancer prevention studies. Cancer Epidemiol Biomarkers Prev 8, 83-89, 1999. (Pubitemid 29090874)
76. Henning SM,Aronson W, NiuY,Conde F, Lee NH,.et al. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr 136, 1839-1843, 2006. (Pubitemid 43973585)
77. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100, 57-70, 2000 (Pubitemid 30046295)
78. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144, 646-674, 2011.
79. Dou QP, Landis-Piwowar KR, Chen D, Huo C, Wan SB,.et al. Green tea polyphenols as a natural tumour cell proteasome inhibitor. Inflammopharmacology 16, 208-212, 2008.
80. Blagosklonny MV, Wu GS, Omura S, and el-Deiry WS: Proteasomedependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 227, 564-569, 1996.
81. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK,.et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37-43, 1995.
82. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, and Miyamoto S. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev 9, 2723-2735, 1995. (Pubitemid 3009952)
83. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G,.et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685, 1995.
84. LiBand Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA 97, 3850-3855, 2000.
85. Nam S, Smith DM, and Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem276, 13322-13330, 2001.
86. Yang CS: Tea and health. Nutrition 15, 946-949, 1999. (Pubitemid 29518486)
87. Sandhu C and Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 24, 107-118, 2000. (Pubitemid 30427696)
88. Sherr CJ: Cancer cell cycles. Science 274, 1672-1677, 1996.
89. Gupta S, Hussain T, and Mukhtar H. Molecular pathway for (-)- epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410, 177-185, 2003. (Pubitemid 36268810)
90. Gupta S, Ahmad N, Nieminen AL, and Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 164, 82-90, 2000. (Pubitemid 30198547)
91. Dotto GP: P21(WAF1/Cip1): More than a break to the cell cycle? Biochim Biophys Acta 1471, M43-M56, 2000.
92. Gartel AL, Serfas MS, and Tyner AL: P21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213, 138-149, 1996.
93. Ortega S, Malumbres M, and Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602, 73-87, 2002. (Pubitemid 34311901)
94. Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287, 821-828, 1999. (Pubitemid 29188868)
95. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML,.et al. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851-4859, 2003. (Pubitemid 36981273)
96. Brizuela L, Dayon A, Doumerc N, Ader I, Golzio M,.et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumorsuppressive tea and wine polyphenols in prostate cancer. FASEB J 24, 3882-3894, 2010.
97. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, and Swinnen JV: Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106, 856-862, 2003. (Pubitemid 37071663)
98. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM,.et al. Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci 68, 1207-1214, 2001. (Pubitemid 32168047)
99. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, and Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 275, 86-92, 2009.
100. Hussain T, Gupta S, Adhami VM, and Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 113, 660-669, 2005. (Pubitemid 40038745)
101. Lyn-Cook BD,Rogers T,YanY,Blann EB, Kadlubar FF,. et al.Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer 35, 80-86, 1999.
102. Pezzato E, Sartor L, Dell'Aica I, Dittadi R, Gion M,.et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 112, 787-792, 2004. (Pubitemid 39435263)
103. Ravindranath MH, Saravanan TS, Monteclaro CC, Presser N, Ye X,.et al. Epicatechins purified from green tea (Camellia sinensis) differentially suppress growth of gender-dependent human cancer cell lines. Evid Based Complement Alternat Med 3, 237-247, 2006.
104. Ren F, Zhang S, Mitchell SH, Butler R, and Young CY: Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19, 1924-1932, 2000. (Pubitemid 30219035)
105. Thomas F, Patel S, Holly JM, Persad R, Bahl A,.et al. Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3- Gallate (EGCG) or an IGF-I receptor inhibitor. Prostate 69, 219-224, 2009.
106. Sartor L, Pezzato E, Dona M, Dell'Aica I, Calabrese F,.et al. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggeredMMP-2activation and invasion in murineTRAMP model. Int J Cancer 112, 823-829, 2004. (Pubitemid 39435267)
107. Pandey M, Shukla S, and Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer 126, 2520-2533, 2010.
108. Harper CE, Patel BB, Wang J, Eltoum IA, and Lamartiniere CA: Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: Mechanisms of action. Prostate 67, 1576-1589, 2007. (Pubitemid 47536156)
109. McCarthy S, Caporali A, Enkemann S, Scaltriti M, Eschrich S,.et al. Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol 1, 196-204, 2007. (Pubitemid 47199136)
110. Nyska A, Suttie A, Bakshi S, Lomnitski L, Grossman S,.et al. Slowing tumorigenic progression in TRAMP mice and prostatic carcinoma cell lines using natural antioxidant from spinach, NAO-a comparative study of three anti-oxidants. Toxicol Pathol 31, 39-51, 2003. (Pubitemid 36169420)
111. Liao S, Umekita Y, Guo J, Kokontis JM, and Hiipakka RA: Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 96, 239-243, 1995.
112. Siddiqui IA, Zaman N, Aziz MH, Reagan-Shaw SR, Sarfaraz S,.et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 27, 833-839, 2006.
113. Kao YH, Hiipakka RA, and Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 141, 980-987, 2000. (Pubitemid 32260441)
114. Hiipakka RA, Zhang HZ, Dai W, Dai Q, and Liao S. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 63, 1165-1176, 2002. (Pubitemid 34267032)
115. Liao S and Hiipakka RA: Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 214, 833-838, 1995.
116. Balk SP, Ko YJ, and Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol 21, 383-391, 2003. (Pubitemid 46606169)
117. Christensson A and Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 220, 45-53, 1994. (Pubitemid 24067552)
118. Wolf DA, Schulz P, and Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol 6, 753-762, 1992.
119. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT,.et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151, 1283-1290, 1994. (Pubitemid 24121936)
120. Lokeshwar BL: MMP inhibition in prostate cancer. Ann NY Acad Sci 878, 271-289, 1999. (Pubitemid 29353576)
121. Rosenzweig SA and Atreya HS: Defining the pathway to insulinlike growth factor system targeting in cancer. Biochem Pharmacol 80, 1115-1124, 2010.
122. Weroha SJ and Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 13, 471-483, 2008.
123. Yu H and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92, 1472-1489, 2000.
124. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, and Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor- I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64, 8715-8722, 2004. (Pubitemid 39552088)
125. Kaplan PJ,Mohan S,Cohen P, Foster BA, and GreenbergNM:The insulinlike growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59, 2203-2209, 1999. (Pubitemid 29217686)
126. Li M, He Z, Ermakova S, Zheng D, Tang F,.et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)- epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 16, 598-605, 2007. (Pubitemid 46548666)
127. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB,.et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 15, 1947-1953, 2009.
128. Arnold JT and Isaacs JT: Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 9, 61-73, 2002. (Pubitemid 34298364)
129. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351, 1488-1490, 2004. (Pubitemid 39315314)
130. Lee EC and Tenniswood M. Programmed cell death and survival pathways in prostate cancer cells. Arch Androl 50, 27-32, 2004. (Pubitemid 38858185)
131. Ferreira CG, Epping M, Kruyt FA, and Giaccone G: Apoptosis: Target of cancer therapy. Clin Cancer Res 8, 2024-2034, 2002. (Pubitemid 34753570)
132. Penn LZ: Apoptosis modulators as cancer therapeutics. Curr Opin Investig Drugs 2, 684-692, 2001. (Pubitemid 32509692)
133. Gupta S, Hastak K, Afaq F, Ahmad N, and Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 23, 2507-2522, 2004. (Pubitemid 38520748)
134. Luo KL, Luo JH, and Yu YP: (-)-Epigallocatechin-3-gallate induces Du145 prostate cancer cell death via downregulation of inhibitor of DNA binding 2, a dominant negative helix-loop-helix protein. Cancer Sci 101, 707-712, 2010.
135. Siddiqui IA,Malik A, Adhami VM, AsimM, Hafeez BB,.et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27, 2055-2063, 2008. (Pubitemid 351442738)
136. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, andMukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 91, 232-242, 2004.
137. Kazi A, Smith DM, Zhong Q, and Dou QP: Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis. Mol Pharmacol 62, 765-771, 2002.
138. Alenzi FQ: Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci 61, 99-102, 2004. (Pubitemid 38879538)
139. Clarke PR and Allan LA: Cell-cycle control in the face of damage-a matter of life or death. Trends Cell Biol 19, 89-98, 2009.
140. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K,.et al. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist Updat 10, 13-29, 2007. (Pubitemid 46636381)
141. Pucci B, Kasten M, and Giordano A: Cell cycle and apoptosis. Neoplasia 2, 291-299, 2000.
142. Pan MH, Lin CC, Lin JK, and Chen WJ: Tea polyphenol (-)- epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. J Agric Food Chem 55, 5030-5037, 2007.
143. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX,.et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52, 183-200, 2002. (Pubitemid 34791221)
144. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V,.et al. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10, 5501-5507, 2004. (Pubitemid 39100488)
145. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X,.et al. The nuclear factorkappaB pathway controls the progression of prostate cancer to androgenindependent growth. Cancer Res 68, 6762-6769, 2008.
146. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P,.et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175, 489-499, 2009.
147. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B,.et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 60, 28-34, 2000.
148. Leskov KS, Klokov DY, Li J, Kinsella TJ, and Boothman DA: Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278, 11590-11600, 2003. (Pubitemid 36792721)
149. Vayalil PK and Katiyar SK: Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells. Prostate 59, 33-42, 2004. (Pubitemid 38387841)
150. Siddiqui IA, Shukla Y, Adhami VM, Sarfaraz S, Asim M,.et al. Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res 25, 2135-2142, 2008.
151. Fuller K,Wong B, Fox S,Choi Y, andChambers TJ:TRANCEis necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J ExpMed 188, 997-1001, 1998. (Pubitemid 28433427)
152. Wong BR, Josien R, Lee SY, Sauter B, Li HL,.et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cellspecific survival factor. J ExpMed 186, 2075-2080, 1997. (Pubitemid 28013694)
153. Darnay BG, Ni J, Moore PA, and Aggarwal BB: Activation of NFkappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274, 7724-7731, 1999.
154. Gittes RF: Carcinoma of the prostate. N Engl J Med 324, 236-245, 1991.
155. Gupta S, Ahmad N, Mohan RR, Husain MM, and Mukhtar H. Prostate cancer chemoprevention by green tea: In vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 59, 2115-2120, 1999. (Pubitemid 29217674)
156. Saleem M, Adhami VM, Ahmad N, Gupta S, and Mukhtar H. Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res 11, 147-153, 2005. (Pubitemid 40075789)
157. Teichert F, Verschoyle RD, Greaves P, Jones DJ,Wilson ID,.et al. Plasma metabolic profiling reveals age-dependency of systemic effects of green tea polyphenols in mice with and without prostate cancer. Mol Biosyst 6, 1911-1916, 2010.
158. Mehlen P and Puisieux A. Metastasis: A question of life or death. Nat Rev Cancer 6, 449-458, 2006.
159. Stetler-Stevenson WG, Aznavoorian S, and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9, 541-573, 1993.
160. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43(Suppl), S42-S51, 1999. (Pubitemid 29244632)
161. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89, 1260-1270, 1997. (Pubitemid 27371946)
162. John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7, 14-23, 2001. (Pubitemid 32591662)
163. Yu AE, Hewitt RE, Connor EW, and Stetler-Stevenson WG: Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 11, 229-244, 1997. (Pubitemid 27421320)
164. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P,.et al. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16, 513-528, 1998. (Pubitemid 29009587)
165. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20, 287-296, 2001. (Pubitemid 34595272)
166. Eatock MM, Schatzlein A, and Kaye SB: Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 26, 191-204, 2000. (Pubitemid 30330664)
167. Fox SB, GaspariniG, and HarrisAL: Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2, 278-289, 2001. (Pubitemid 33591566)
168. Kerbel RS: Tumor angiogenesis. N Engl J Med 358, 2039-2049, 2008. (Pubitemid 351656458)
169. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D,.et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54, 523-527, 1999. (Pubitemid 29407032)
170. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D,.et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85, 276-280, 2000. (Pubitemid 30088518)
171. Thurston G: Role of angiopoietins and tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314, 61-68, 2003. (Pubitemid 37409913)
172. Adhami VM, Ahmad N, and Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 133, 2417S-2424S, 2003. (Pubitemid 36828848)
173. Wang SI and Mukhtar H. Gene expression profile in human prostate LNCaP cancer cells by (-)-epigallocatechin-3-gallate. Cancer Lett 182, 43-51, 2002. (Pubitemid 34518655)
174. Scaltriti M, Belloni L, Caporali A, Davalli P, Remondini D,.et al. Molecular classification of green tea catechin-sensitive and green tea catechinresistant prostate cancer in the TRAMP mice model by quantitative realtime PCR gene profiling. Carcinogenesis 27, 1047-1053, 2006.
175. Bettuzzi S, Rizzi F, and Belloni L: Clinical relevance of the inhibitory effect of green tea catechins (GtCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: An integrated view. Pol J Vet Sci 10, 57-60, 2007. (Pubitemid 46447161)
176. Duhon D, Bigelow RL, Coleman DT, Steffan JJ, Yu C,.et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog 49, 739-749, 2010.
177. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C,.et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60, 1541-1545, 2000. (Pubitemid 30183422)
178. Beltz LA, Bayer DK, Moss AL, and Simet IM: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 6, 389-406, 2006. (Pubitemid 44377775)
179. Khan N, Afaq F, Saleem M, Ahmad N, and Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3- gallate. Cancer Res 66, 2500-2505, 2006.
180. Lin JK, Liang YC, and Lin-Shiau SY: Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 58, 911-915, 1999.
181. Pandey M and Gupta S. Green tea and prostate cancer: From bench to clinic. Front Biosci (Elite Ed) 1, 13-25, 2009.
182. Saleem M, Adhami VM, Siddiqui IA, and Mukhtar H. Tea beverage in chemoprevention of prostate cancer: A mini-review. Nutr Cancer 47, 13-23, 2003. (Pubitemid 38250431)
183. Baud V and Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40, 2009.
184. Dutta J, Fan Y, Gupta N, Fan G, and Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25, 6800-6816, 2006. (Pubitemid 44657853)
185. Lee CH, Jeon YT, Kim SH, and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29, 19-35, 2007. (Pubitemid 46985299)
186. Sardana G, Dowell B, and Diamandis EP: Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54, 1951-1960, 2008. (Pubitemid 352774027)
187. Thomas R and Kim MH: Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 334, 543-548, 2005. (Pubitemid 40982400)
188. Zhou YD, Kim YP, Li XC, Baerson SR, Agarwal AK,.et al. Hypoxiainducible factor-1 activation by (-)-epicatechin gallate: Potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J Na Prod 67, 2063-2069, 2004. (Pubitemid 40092556)
189. Stuart EC, Scandlyn MJ, and Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 79, 2329-2336, 2006. (Pubitemid 44772933)
190. Chow HH, Hakim IA, Vining DR, Crowell JA, Tome ME,.et al. Modulation of human glutathione s-transferases by polyphenon e intervention. Cancer Epidemiol Biomarkers Prev 16, 1662-1666, 2007. (Pubitemid 47294835)
191. Yang CS, Lambert JD, Hou Z, Ju J, Lu G,.et al. Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog 45, 431-435, 2006. (Pubitemid 43865851)
192. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y,.et al. Tea polyphenol (-)- epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63, 7563-7570, 2003. (Pubitemid 37466673)
193. Chen L and Zhang HY: Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules 12, 946-957, 2007.
194. Yang K, Fan K, Newmark H, Leung D, Lipkin M,.et al. Cytokeratin, lectin, and acidic mucin modulation in differentiating colonic epithelial cells of mice after feedingWestern-style diets. Cancer Res 56, 4644-4648, 1996. (Pubitemid 26338064)
195. Pandey M and Gupta S. Green tea polyphenols inhibit promoter hypermethylation through the downregulation of DNMT expression in prostate cancer LNCaP cells. Paper presented at 98th AACR AnnualMeeting, Los Angeles, CA, April 14-18, 2007